{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=docetaxel&page=49", "query": { "intervention": "docetaxel", "page": 49 }, "page_size": 10 }, "pagination": { "page": 49, "page_size": 10, "total_count": 1321, "total_pages": 133, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=docetaxel&page=50&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=docetaxel&page=48&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T06:21:09.602Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07017673", "title": "Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "TNBC", "TNBC - Triple-Negative Breast Cancer", "Early Stage Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Ivonescimab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cedars-Sinai Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2025-07-25", "completion_date": "2032-11", "has_results": false, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-10-31T06:21:09.602Z", "location_count": 4, "location_summary": "Los Angeles, California • Pasadena, California • Torrance, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07017673" }, { "nct_id": "NCT00201708", "title": "Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide in Axillary Node-Positive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide (AC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 56, "start_date": "2004-10", "completion_date": "2014-02", "has_results": false, "last_update_posted_date": "2016-09-02", "last_synced_at": "2026-10-31T06:21:09.602Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00201708" }, { "nct_id": "NCT00450008", "title": "Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "GM-CSF", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Methodist Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 9, "start_date": "2006-12", "completion_date": "2008-09", "has_results": false, "last_update_posted_date": "2016-03-17", "last_synced_at": "2026-10-31T06:21:09.602Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00450008" }, { "nct_id": "NCT00043576", "title": "ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "calcitriol", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novacea", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 250, "start_date": "2002-08", "completion_date": "2005-12", "has_results": false, "last_update_posted_date": "2009-03-12", "last_synced_at": "2026-10-31T06:21:09.602Z", "location_count": 52, "location_summary": "Montgomery, Alabama • Scottsdale, Arizona • Tucson, Arizona + 44 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00043576" }, { "nct_id": "NCT00044993", "title": "Chemotherapy Combined With Gene Therapy in Treating Patients Who Have Stage III or Stage IV Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Ad5CMV-p53 gene", "type": "BIOLOGICAL" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Introgen Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2002-02", "completion_date": "2004-08", "has_results": false, "last_update_posted_date": "2013-05-30", "last_synced_at": "2026-10-31T06:21:09.602Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00044993" }, { "nct_id": "NCT00833326", "title": "A Study of ARRY-334543 and Docetaxel in Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "ARRY-334543, EGFR/ErbB2 inhibitor; oral", "type": "DRUG" }, { "name": "Docetaxel, mitotic inhibitor; intravenous", "type": "DRUG" }, { "name": "Prophylactic growth factors; subcutaneous", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Array Biopharma, now a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2009-01", "completion_date": "2010-07", "has_results": false, "last_update_posted_date": "2020-10-06", "last_synced_at": "2026-10-31T06:21:09.602Z", "location_count": 3, "location_summary": "Aurora, Colorado • Rochester, Minnesota • Nashville, Tennessee", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00833326" }, { "nct_id": "NCT01351415", "title": "A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Squamous Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 485, "start_date": "2011-06-25", "completion_date": "2016-06-25", "has_results": true, "last_update_posted_date": "2017-09-18", "last_synced_at": "2026-10-31T06:21:09.602Z", "location_count": 68, "location_summary": "Mobile, Alabama • Glendale, Arizona • Jonesboro, Arkansas + 61 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Burbank", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01351415" }, { "nct_id": "NCT01705483", "title": "A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pharmacokinetics of ASP9853", "Non-hematologic Malignancies" ], "interventions": [ { "name": "ASP9853", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2012-08-28", "completion_date": "2014-06-11", "has_results": false, "last_update_posted_date": "2024-11-07", "last_synced_at": "2026-10-31T06:21:09.602Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Detroit, Michigan • Nashville, Tennessee", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01705483" }, { "nct_id": "NCT00217529", "title": "Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Fallopian Tube Cancer", "Ovarian Cancer", "Peritoneal Cavity Cancer" ], "interventions": [ { "name": "pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "erlotinib hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": "2004-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-09-21", "last_synced_at": "2026-10-31T06:21:09.602Z", "location_count": 3, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00217529" }, { "nct_id": "NCT05712694", "title": "Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Soft Tissue Sarcoma" ], "interventions": [ { "name": "ADI PEG20", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Polaris Group", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 218, "start_date": "2023-11-29", "completion_date": "2026-05-25", "has_results": false, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-10-31T06:21:09.602Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 21 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05712694" } ] }